NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free OPTN Stock Alerts $0.93 -0.04 (-4.14%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.89▼$0.9650-Day Range$0.89▼$1.9452-Week Range$0.86▼$2.10Volume571,324 shsAverage Volume547,842 shsMarket Capitalization$104.24 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get OptiNose alerts: Email Address OptiNose MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside332.3% Upside$4.00 Price TargetShort InterestHealthy2.76% of Shares Sold ShortDividend StrengthN/ASustainability-2.10Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$138,078 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector325th out of 909 stocksPharmaceutical Preparations Industry144th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.76% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in OptiNose has recently decreased by 2.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OptiNose is -2.10. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,078.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.26) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About OptiNose Stock (NASDAQ:OPTN)OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Read More OPTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPTN Stock News HeadlinesApril 7, 2024 | msn.comOptinose to Present at Needham Virtual Healthcare ConferenceApril 6, 2024 | finance.yahoo.comOptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years agoApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 4, 2024 | globenewswire.comOptinose to Present at the Needham Virtual Healthcare ConferenceMarch 16, 2024 | finanznachrichten.deOptinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 16, 2024 | msn.comOptiNose granted FDA nod to expand labeling for sinusitis therapyMarch 15, 2024 | bizjournals.comBucks County's Optinose wins FDA approval for wider use of flagship productMarch 15, 2024 | globenewswire.comXHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 13, 2024 | bizjournals.comOptinose primed for FDA ruling on Xhance that could 'reshape' its futureMarch 10, 2024 | finance.yahoo.comUS$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest ResultsMarch 10, 2024 | seekingalpha.comOptiNose, Inc. (OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comOptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comOptiNose Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...March 7, 2024 | investorplace.comOPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deOptinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | finance.yahoo.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | msn.comOptiNose reports mixed results; initiates Q1 and FY24 outlookMarch 7, 2024 | washingtonpost.comOptiNose: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 6, 2024 | benzinga.comOptiNose's Earnings: A PreviewFebruary 29, 2024 | globenewswire.comOptinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsFebruary 29, 2024 | entrepreneur.com3 Pharma Stocks to Consider for March GainsJanuary 18, 2024 | finance.yahoo.comOptinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeDecember 6, 2023 | msn.comWhy ENT-Focused OptiNose Shares Are Diving TodayDecember 6, 2023 | finance.yahoo.comOptinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCESee More Headlines Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+332.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,480,000.00 Net Margins-50.06% Pretax Margin-49.99% Return on EquityN/A Return on Assets-33.05% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.55 Sales & Book Value Annual Sales$70.99 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-1.20Miscellaneous Outstanding Shares112,650,000Free Float110,174,000Market Cap$104.24 million OptionableNot Optionable Beta-0.24 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ramy A. Mahmoud M.D. (Age 59)M.P.H., CEO & Director Comp: $731.59kMr. Michael F. Marino Esq. (Age 48)Chief Legal Officer & Corporate Secretary Comp: $604.24kMr. Anthony J. Krick (Age 43)Vice President & Chief Accounting Officer Mr. Jonathan NeelyVice President of Investor Relations & Business OperationsMs. Karen E. Brophy (Age 61)Chief Human Resources Officer & VP of Human Resources Mr. Paul Spence (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsCyteir TherapeuticsNASDAQ:CYTTCartesian TherapeuticsNASDAQ:RNACImmunicNASDAQ:IMUXFibroGenNASDAQ:FGENCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 50,662 shares on 4/24/2024Ownership: 0.077%Rice Hall James & Associates LLCSold 11,619 shares on 4/23/2024Ownership: 0.882%Kingdon Capital Management L.L.C.Bought 200,000 shares on 3/18/2024Ownership: 3.461%Ramy A MahmoudSold 19,198 sharesTotal: $36,092.24 ($1.88/share)Michael F Marino IIISold 15,059 sharesTotal: $28,310.92 ($1.88/share)View All Insider TransactionsView All Institutional Transactions OPTN Stock Analysis - Frequently Asked Questions Should I buy or sell OptiNose stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPTN shares. View OPTN analyst ratings or view top-rated stocks. What is OptiNose's stock price target for 2024? 3 equities research analysts have issued twelve-month target prices for OptiNose's stock. Their OPTN share price targets range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 332.3% from the stock's current price. View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts. How have OPTN shares performed in 2024? OptiNose's stock was trading at $1.29 at the beginning of 2024. Since then, OPTN shares have decreased by 28.3% and is now trading at $0.9253. View the best growth stocks for 2024 here. When is OptiNose's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OPTN earnings forecast. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The business had revenue of $19.87 million for the quarter, compared to the consensus estimate of $19.90 million. During the same quarter in the previous year, the firm earned ($0.17) EPS. What guidance has OptiNose issued on next quarter's earnings? OptiNose updated its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.0 million-$13.0 million, compared to the consensus revenue estimate of $18.2 million. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX). When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO. Who are OptiNose's major shareholders? OptiNose's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.88%) and Assenagon Asset Management S.A. (0.08%). Insiders that own company stock include Anthony J Krick, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli. View institutional ownership trends. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPTN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
